OncoMatch/Clinical Trials/NCT05876806
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Is NCT05876806 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dabrafenib and Trametinib for cancer.
Treatment: Dabrafenib · Trametinib — This is a Phase II, open-label, non-randomized, multi-center study of oral Dabrafenib in combination with oral Trametinib in subjects with solid tumors with BRAF V600E mutation or clinically actionable BRAF gene alterations.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: BRAF V600E mutation
BRAF V600 mutated advanced solid tumor
Required: BRAF V600K mutation
BRAF V600 mutated advanced solid tumor
Required: BRAF other BRAF gene alterations that are regarded to be actionable by the KOSMOS MTB
Patients with other BRAF gene alterations that are regarded to be actionable by the KOSMOS MTB
Excluded: RAS activating mutation
History of malignancies with confirmed activating RAS mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: braf inhibitor (dabrafenib, vemurafenib, encorafenib)
Cannot have received: mek inhibitor (trametinib, binimetinib, selumetinib, cobimetinib)
Cannot have received: erk inhibitor (ravoxertinib, ulixertinib, cc-90003, mk-8353)
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Cardiac function
No LVEF below institutional lower limit of normal, QTc < 480 msec, no clinically significant uncontrolled arrhythmias, no moderate valvular thickening, no intra-cardiac defibrillators, no acute coronary syndromes within 6 months, no congestive heart failure ≥ Class II (NYHA)
Adequate bone marrow and organ function. Current evidence of cardiovascular risk including any of the following: Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal, QT interval corrected for heart rate using Bazett's formula ≥ 480 msec, Clinically significant uncontrolled arrhythmias, Moderate valvular thickening documented by echocardiography, Presence of intra-cardiac defibrillators, Acute coronary syndromes (including myocardial infarction and unstable angina) which required coronary angioplasty or stenting within 6 months before enrollment, Congestive heart failure ≥ Class II as defined by New York Heart Association
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify